LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Strona główna・Stock List・Novartis AG

Novartis AG

Closed

148.01 -1.18

Buy Sell

Overview

Share price change

24h

Current

Min

147.68

Max

148.3

Key metrics
By Trading Economics
Income	747M 3.2B
Sales	189M 14B
P/E Sector Avg	20.777 51.415
EPS	1.99
Dividend yield	3.26
Profit margin	23.336
Employees	75,267
EBITDA	338M 5.4B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+14.65% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	3.26% 2.34%

Market Stats
By TradingEconomics
Market Cap	-1.2B 277B
Previous open	149.19
Previous close	148.01

Technical Score

By Trading Central

Confidence

Bearish Evidence

N/A / 112.63 Support & Resistance

Novartis AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 kwi 2026, 09:05 UTC

Earnings

Novartis Earnings Hit by Generic Competition -- Update

28 kwi 2026, 05:51 UTC

Earnings

Novartis Could Upgrade Future Growth Outlook

27 mar 2026, 10:24 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27 mar 2026, 06:36 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28 kwi 2026, 09:18 UTC

Market Talk

Earnings

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28 kwi 2026, 07:26 UTC

Market Talk

Earnings

Novartis's Results Are Mixed -- Market Talk

28 kwi 2026, 05:07 UTC

Earnings

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28 kwi 2026, 05:05 UTC

Earnings

Novartis: On Track to Deliver Full-Year Guiance

28 kwi 2026, 05:04 UTC

Earnings

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28 kwi 2026, 05:04 UTC

Earnings

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28 kwi 2026, 05:03 UTC

Earnings

Novartis 1Q Core EPS $1.99

28 kwi 2026, 05:03 UTC

Earnings

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28 kwi 2026, 05:02 UTC

Earnings

Novartis 1Q Core Operating Profit $4.90B

28 kwi 2026, 05:02 UTC

Earnings

Analysts Saw Novartis 1Q Sales at $13.34B

28 kwi 2026, 05:01 UTC

Earnings

Novartis 1Q Sales $13.11B

28 kwi 2026, 05:00 UTC

Earnings

Novartis Backs 2026 View

28 kwi 2026, 05:00 UTC

Earnings

Novartis AG 1Q EPS $1.65

28 kwi 2026, 05:00 UTC

Earnings

Novartis AG 1Q Net Pft $3.2B

28 kwi 2026, 05:00 UTC

Earnings

Novartis AG 1Q Adj EPS $1.99

24 kwi 2026, 05:20 UTC

Earnings

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24 kwi 2026, 05:19 UTC

Earnings

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24 kwi 2026, 05:19 UTC

Earnings

Novartis: Prequalification Is a Process Run by the WHO

10 kwi 2026, 11:45 UTC

Market Talk

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2 kwi 2026, 08:01 UTC

Market Talk

Novartis Likely to Confirm Guidance -- Market Talk

30 mar 2026, 09:37 UTC

Market Talk

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27 mar 2026, 07:54 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27 mar 2026, 06:22 UTC

Acquisitions, Mergers, Takeovers

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27 mar 2026, 06:05 UTC

Acquisitions, Mergers, Takeovers

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27 mar 2026, 06:04 UTC

Acquisitions, Mergers, Takeovers

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27 mar 2026, 06:03 UTC

Acquisitions, Mergers, Takeovers

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Peer Comparison

Price change

Novartis AG Forecast

Price Target

By TipRanks

14.65% upside

12 Months Forecast

Average 169.78 USD 14.65%

High 180 USD

Low 141 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Novartis AG - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 112.63Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.